IBUTAMOREN MESILATE ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
78Hypopituitarism1

78. Hypopituitarism


Clinical trials : 494 Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000874-92-PL
(EUCTR)
22/03/202126/10/2020A Multicenter, 12-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)A Multicenter, 12-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD) - LUM-201-01 Growth hormone deficiency
MedDRA version: 20.0;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Name: LUM-201
INN or Proposed INN: Ibutamoren mesilate
Other descriptive name: IBUTAMOREN MESILATE
Product Name: LUM-201
INN or Proposed INN: Ibutamoren mesilate
Other descriptive name: IBUTAMOREN MESILATE
Product Name: LUM-201
INN or Proposed INN: Ibutamoren mesilate
Other descriptive name: IBUTAMOREN MESILATE
Trade Name: Norditropin
INN or Proposed INN: recombinant human growth hormone
Other descriptive name: recombinant human growth hormone
Trade Name: Norditropin
INN or Proposed INN: recombinant human growth hormone
Other descriptive name: recombinant human growth hormone
Lumos Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 2United States;Poland;Ukraine;Australia;Russian Federation;Israel;New Zealand